China National Biotec Group (CNBG), a wholly-owned affiliate of Chinese healthcare group Sinopharm, is picking up a stake in US-based aesthetic gel implant technology developer Advanced Aesthetic Technologies (AAT) to serve the largely unmet medical aesthetics market in China.
Continue reading this premium story with a subscription to DealStreetAsia.Subscribe
Already a Subscriber? Log in
Contact us for corporate subscriptions at email@example.com